Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Merck's Mylanta AR covered under Pepcid AC NDA.

This article was originally published in The Tan Sheet

Executive Summary

MYLANTA AR COVERED UNDER PEPCID AC NDA, according to J&J/Merck. The company was not required to submit a new NDA for the Mylanta acid blocker, which contains 10 mg famotidine -- the same active ingredient at the same dose as J&J/Merck's Pepcid AC. The company launched Pepcid AC, which was first to market in the acid blocker category and is the top-selling H2 antagonist, in June 1996.

You may also be interested in...



Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication

Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients

Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication

Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients

Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication

Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients

Topics

UsernamePublicRestriction

Register

PS086558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel